NCT05541250View on ClinicalTrials.gov

Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 4, 2023

Primary Completion Date

September 29, 2026

Study Completion Date

September 29, 2026

Conditions
Peripheral Nerve Injury
Interventions
BIOLOGICAL

Autologous Human Schwann Cell

A one-time dose of 1000 μl\* or 80 to 100 million ahSC prepared from segments of the sural nerve from the leg recovered from the participant.

Trial Locations (1)

33136

RECRUITING

University of Miami, Miami

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

W. Dalton Dietrich

OTHER